About 2.5 million persons in the US had hepatitis C between 2017 and 2020.1 Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.2
GENOTYPE PREVALENCE — About 70-75% of HCV infections in the US are caused by HCV genotype 1 (~50% are caused by genotype 1a), and about 20-25% are caused by genotype 2 or 3. HCV genotype 3 is associated with faster disease progression and increased rates of...
- In Brief: Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis
- In Brief: FluMist Influenza Vaccine for Self-Administration
- COVID-19 Update: Novavax Vaccine for 2024-2025
- Figure 1: Treatment of Hepatitis C Virus Infection in Treatment-Naive Adults (online only)
- Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
- Lazertinib (Lazcluze) for Non-Small Cell Lung Cancer (online only)
- Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
- An Epinephrine Nasal Spray (neffy) for Anaphylaxis
- Vonoprazan (Voquezna) for Nonerosive GERD
- A New RSV Vaccine (mResvia) for Adults ≥60 Years Old
- In Brief: New Warning for Fezolinetant (Veozah)
- Figure 1: Pneumococcal Vaccine Recommendations for Adults 19-64 Years Old (online only)
- Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)
- Addendum: Effectiveness of mRNA COVID-19 Vaccines (online only)
- In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)
- In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)
RELEASE
The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥6 years old. Clonidine ER tablets have been available for years for treatment of ADHD in children 6-17 years old.
STANDARD TREATMENT — Stimulants such as amphetamines and methylphenidate are the drugs of choice for treatment of ADHD. They are classified as schedule II controlled substances. The alpha2-agonists clonidine and guanfacine (Intuniv, and generics) and the selective norepinephrine reuptake inhibitors atomoxetine (Strattera, and generics) and viloxazine (Qelbree), which are not controlled substances, can …